Page 91 - Read Online

Page 12 of 12 Bongiovanni et al. J Cancer Metastasis Treat 2022;8:44 https://dx.doi.org/10.20517/2394-4722.2022.78

tumors. Angiogenesis 2019;22:473-5. DOI PubMed PMC
57. Song Q, Zhang CD, Wu XH. Therapeutic cancer vaccines: from initial findings to prospects. Immunol Lett 2018;196:11-21. DOI
PubMed
58. Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN. Immunotherapy of murine malignant mesothelioma using tumor
lysate-pulsed dendritic cells. Am J Respir Crit Care Med 2005;171:1168-77. DOI PubMed
59. Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant
mesothelioma. Am J Respir Crit Care Med 2010;181:1383-90. DOI PubMed
60. Cornelissen R, Hegmans JP, Maat AP, et al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide
as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med 2016;193:1023-31. DOI PubMed
61. Belderbos RA, Baas P, Berardi R, et al. A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor
cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell immunotherapy for
mesothelioma (DENIM) trial. Transl Lung Cancer Res 2019;8:280-5. DOI PubMed PMC
62. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011;239:62-84. DOI PubMed
63. Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother 2014;10:3153-64.
DOI PubMed PMC
64. Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin
Immunol 2011;23:399-406. DOI PubMed
65. McNamara MA, Nair SK, Holl EK. RNA-based vaccines in cancer immunotherapy. J Immunol Res 2015;2015:794528. DOI PubMed
PMC
66. Pease DF, Kratzke RA. Oncolytic viral therapy for mesothelioma. Front Oncol 2017;7:179. DOI PubMed PMC
67. Msaouel P, Opyrchal M, Dispenzieri A, et al. Clinical trials with oncolytic measles virus: current status and future prospects. Curr
Cancer Drug Targets 2018;18:177-87. DOI PubMed PMC
68. Eguchi T, Kadota K, Mayor M, et al. Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and
coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget 2017;8:77872-82. DOI PubMed PMC
69. Zauderer MG, Tsao AS, Dao T, et al. A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after
multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res 2017;23:7483-9. DOI PubMed PMC
70. Hassan R, Alley E, Kindler H, et al. Clinical response of live-attenuated, Listeria monocytogenes expressing mesothelin (CRS-207)
with chemotherapy in patients with malignant pleural mesothelioma. Clin Cancer Res 2019;25:5787-98. DOI PubMed PMC
71. Rossini M, Rizzo P, Bononi I, et al. New perspectives on diagnosis and therapy of malignant pleural mesothelioma. Front Oncol
2018;8:91. DOI PubMed PMC
72. Harber J, Kamata T, Pritchard C, Fennell D. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications
for checkpoint blockade efficacy. J Immunother Cancer 2021;9:e003032. DOI PubMed PMC
73. Rijavec E, Biello F, Barletta G, Dellepiane C, Genova C. Novel approaches for the treatment of unresectable malignant pleural
mesothelioma: a focus on immunotherapy and target therapy (Review). Mol Clin Oncol 2022;16:89. DOI PubMed PMC
74. Brockwell NK, Alamgeer M, Kumar B, Rivalland G, John T, Parker BS. Preliminary study highlights the potential of immune
checkpoint inhibitors in sarcomatoid mesothelioma. Transl Lung Cancer Res 2020;9:639-45. DOI PubMed PMC